Cardio- and cerebrovascular risk with conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS) in rheumatic arthritis (RA): a real-world comparative assesment
Hauptverfasser: | , , , , , , , , , |
---|---|
Format: | Conference item |
Veröffentlicht: |
2020
|
Zusammenfassung: |
---|